中性粒细胞检测评估植入免疫相容性。

A Polymorphonuclear Leukocyte Assay to Assess Implant Immunocompatibility.

机构信息

1Charité-Universitätsmedizin Berlin, BCRT-Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany.

2Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

出版信息

Tissue Eng Part C Methods. 2019 Aug;25(8):500-511. doi: 10.1089/ten.TEC.2019.0105.

DOI:10.1089/ten.TEC.2019.0105

PMID:31337288

Abstract

Polymorphonuclear leukocytes (PMNs) are essential in the first infection and host-versus-graft reactions. Strategies for adequate and standardized assays to test PMN activation by diverse types of matrices such as cardiovascular implants are urgently needed. To overcome this limitation, we established a straightforward PMN activation assay and validated lipopolysaccharide (LPS) as a reliable PMN activator that induces defined changes in surface marker expression and cytokine release. Biological "proof-of-principle" matrices demonstrated the feasibility of this PMN assay. Overall, this assay provides an instrument conducting an initial immunological assessment of biological implants prior their clinical application.

摘要

多形核白细胞（PMN）在初次感染和宿主移植物反应中至关重要。迫切需要制定充分和标准化的策略，以测试心血管植入物等多种基质对PMN 的激活作用。为了克服这一限制，我们建立了一种简单的PMN 激活测定法，并验证了脂多糖（LPS）作为一种可靠的PMN 激活剂，可诱导表面标记物表达和细胞因子释放的明确变化。生物“原理验证”基质证明了这种PMN 测定法的可行性。总的来说，该测定法为临床应用前的生物植入物的初步免疫评估提供了一种手段。